Delivers targeted RNA therapeutics to the heart to treat cardiomyopathies, aiming to transform the standard of care for people living with these conditions. Proprietary platform combines monoclonal antibody and other targeting ligands’ tissue selectivity with precision oligonucleotide therapeutics; pipeline includes candidates for PRKAG2 syndrome and PLN cardiomyopathy.